CD47 and cancer: In conclusion, mRNA and/or protein expression levels of SLAMF7 on hematopoietic cancer cells should not be used as selection/exclusion criterion for future clinical studies that evaluate the therapeutic potential of CD47-blockade or the combination with CD47 blocking therapy.